MetaCap

Cullinan Therapeutics (CGEM) vs Surrozen (SRZN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Surrozen (SRZN) has outperformed Cullinan Therapeutics (CGEM) over the past year, gaining 115.6% versus a loss of 6.1%. Over five years, CGEM leads with a -51.2% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $577.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGEM-6.12%SRZN+115.61%
+167%+76%-14%
Nov 21, 20251 yearNov 20, 2026
CGEM-54.34%SRZN-79.38%
+53%-25%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGEM versus SRZN key metrics
MetricCGEMSRZN
Share price$8.89$28.46
Market cap$577.15M$596.40M
1-day change-1.98%-7.21%
YTD return-14.11%+25.93%
1-year return-6.12%+115.61%
5-year return-51.21%-78.97%
EPS (TTM)$-3.09$-41.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.48M
Revenue growth (YoY)—-67.37%
Net income (latest FY)$-219.88M$-242.03M
Operating margin—-1210.58%
Net margin—-6960.77%
52-week high$23.19$37.83
52-week low$8.47$12.79
Distance from 52-week high-61.66%-24.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+285.49%+123.12%
Average volume997.14K537.16K
Shares outstanding64.92M20.96M
Employees10944
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SRZN has outperformed CGEM by 121.7 percentage points over the past year.

About Cullinan Therapeutics

CGEM stock →

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

About Surrozen

SRZN stock →

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees

CGEM vs SRZN FAQ

Which is bigger, Cullinan Therapeutics or Surrozen?

Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $577.15M for Cullinan Therapeutics (CGEM).

Which stock has performed better over the past year, CGEM or SRZN?

SRZN returned +115.61% over the past 12 months, compared with -6.12% for CGEM (price return, excluding dividends). Past performance does not predict future results.

Are Cullinan Therapeutics and Surrozen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons